Biophytis SA (FR:ALBPS) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Biophytis SA has received FDA approval to commence a phase 2 clinical study of BIO101 for obesity, focusing on muscle strength and mobility improvements. Anticipated to start in mid-2024 in the USA, the study’s prelim results are expected in 2025. The company is actively seeking funding and partnerships to advance this study in the growing obesity treatment market.
For further insights into FR:ALBPS stock, check out TipRanks’ Stock Analysis page.